[1] Bendoraite A,Knouf EC,Garg KS.Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer:evidence supporting a mesothelial-to-epithelial transition[J]. Gynecol Oncol,2010,116(1):117-125.[2] Marchini S,Cavalieri D,Fruscio R,et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer:a retrospective study of two independent tumour tissue collections[J]. Lancet Oncol,2011,6(2):273-285.[3] Kurman RJ,Shihe IM.The origin and pathogenesis of epithelial ovarian cancer:A proposed unifying theory[J].Am J Surg Pathol,2010,34(3):433-443.[4] 罗建桥,鲍春晓,周建维. miR-126调控SKOV3卵巢癌细胞周期的实验研究[J].中国医药导报,2014,37(19):21-23,27.[5] 刘娜,曾洁,张小媚,等. miR-200a参与调控卵巢癌化疗敏感性的作用及其机制[J].中华医学杂志,2014,94(27):2148-2151.[6] Clark EA,Golub TR,Lander ES,et al.Genomic analysis of metastasis reveals an essential role for RhoC[J].Nature,2000,406(6840):532-535.[7] 郑建坤.RhoC及其与肿瘤作用的研究进展[J].国际泌尿系统杂志,2013,33(3):379-382.[8] 郁玲玲. Rho亚家族在肿瘤侵袭中的作用研究进展[J].复旦学报:医学版,2010,37(5):617-619.[9] 江若安,叶枫,王新宇,抑制TUBA1C的过表达在卵巢癌细胞株CAOV3、SKOV3细胞增殖侵袭中的作用机制探讨[J].浙江医学,2014,32(8):644-647.[10] 范钰,徐娟,周永静,等.RNA干扰下调叉头转录因子M1基因对人肿瘤细胞生长、克隆和侵袭的影响[J].中华实验外科杂志,2014,31(7):1543-1546.[11] 李圃,李冬田,尹冰楠,等.融合基因CDglyES重组腺病毒对卵巢癌细胞抑制作用的体外研究[J].中国肿瘤临床,2014,35(13):861-865. |